Abstract
Introduction:
PARP inhibition is an exciting new anticancer strategy. Olaparib has recently obtained a first in class license in Europe and the USA for the treatment of relapsed BRCA-mutant ovarian cancer.
Areas covered:
We review the key preclinical and clinical data surrounding its use in the maintenance setting. Expert commentary: We also consider the market profile, regulatory issues surrounding the agent and offer a five year speculative viewpoint of its future development in ovarian cancer.
Keywords:
BRCA; Ovarian cancer; PARP inhibitor; homologous recombination; maintenance; olaparib; synthetic lethality.
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Female
-
Genes, BRCA1
-
Genes, BRCA2
-
Humans
-
Mutation
-
Neoplasm Recurrence, Local
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / pathology
-
Phthalazines / adverse effects
-
Phthalazines / pharmacology
-
Phthalazines / therapeutic use*
-
Piperazines / adverse effects
-
Piperazines / pharmacology
-
Piperazines / therapeutic use*
-
Poly(ADP-ribose) Polymerase Inhibitors / adverse effects
-
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
-
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Substances
-
Antineoplastic Agents
-
Phthalazines
-
Piperazines
-
Poly(ADP-ribose) Polymerase Inhibitors
-
olaparib